Drug Resistance: One of the primary concerns is the potential development of resistance to both the artemisinin component and the partner drug. Continuous monitoring and the development of new combinations are essential to mitigate this risk. Access and Distribution: Ensuring widespread access to ACTs in remote and resource-limited settings is a significant challenge. Efforts need to be made to improve the supply chain and reduce costs. Adherence: Patient adherence to the full course of treatment is critical to the success of ACTs. Incomplete courses can lead to treatment failure and the development of resistance.
